**Core tip:** This is the first study to report the prevalence of Epstein-Barr virus (EBV)-associated gastric carcinomas (EBVaGC) in Portugal. The EBVaGCs were found in 8.4% of all gastric cancer cases, being more frequent in upper and middle regions of the stomach and among tubular and medullary carcinomas. Patients with EBV-positive tumours also have a significant lower number of regional lymph nodes with metastasis and a tendency for a better prognosis.

INTRODUCTION
============

Gastric cancer (GC) is the fifth most common malignancy worldwide with nearly one million new cases estimated in 2012 (952000 cases) and despite the significant reduction of its incidence, GC still remains the third leading cause of death by cancer\[[@B1],[@B2]\]. Portugal is one of the European countries with the higher GC incidence and mortality rates, where GC represents the fifth most common cancer with about 3000 new cases per year and with 1387 deaths in men and 898 in women\[[@B1],[@B2]\].

Epstein-Barr virus (EBV) is one of the most common viruses and has been associated with several malignancies including Burkitt's Lymphoma, Hodgkin Lymphoma, post-transplant lymphoproliferative disease, a subset of T/NK cell lymphomas and nasopharyngeal carcinoma\[[@B3]\]. Recently, EBV has been associated with the development of GC, with several reports pointing that E BV-associated GC (EBVaGC) might account for nearly 10% of all GC cases\[[@B4],[@B5]\]. The mechanisms of EBVaGC carcinogenesis are not well understood although some authors have suggested that EBV infection can represent a late event after *Helicobacter pylori* (*H*. *pylori*) infection\[[@B6],[@B7]\].

The presence of EBV in patients with gastric carcinoma was first reported in gastric lymphoepithelioma-like carcinomas (also classified as medullary carcinomas, gastric carcinomas with lymphoid stroma or uncommon variant), nevertheless it has been detected in different histopathological subtypes of gastric carcinoma\[[@B8],[@B9]\]. The majority of GC are adenocarcinomas and are classified according to the Lauren or World Health Organization (WHO) classification system\[[@B10]\]. These classification systems have a reduced clinical utility and recent studies suggested a new classification based on molecular features of tumours, where EBVaGC arises as a new subtype of gastric cancer\[[@B11],[@B12]\].

Despite the high incidence of both GC and EBV infection prevalence in the Portuguese population, there are no studies reporting the prevalence of EBVaGC in Portugal\[[@B2],[@B13]\]. We aimed to determine the prevalence and characteristics of EBVaGC and analyse the profile of EBV latent proteins expressed in gastric tumours from the North Region of Portugal.

MATERIALS AND METHODS
=====================

Study description
-----------------

We have developed a retrospective study in a cohort of 179 consecutive patients diagnosed with gastric cancer and submitted to surgery at the Portuguese Institute of Oncology of Porto (IPO Porto FG EPE) in 2011. Inclusion criteria: (1) patients with histologically confirmed gastric cancer; (2) submitted to gastrectomy (total or partial); and (3) with representative tumour blocks for adequate evaluation of EBV presence.

All tumour samples were histologically examined by a senior pathologist and classified according to the WHO classification system\[[@B10],[@B14]\]. All clinical and pathological data was collected from individual clinical records and inserted on a database with unique codification. TNM-staging was performed in accordance to the UICC/AJCC system 7^th^ edition\[[@B14]\]. The clinical outcome of the patients was followed from the date of surgery to either the date of death or 1st August 2016. All procedures were approved by the Ethical Committee of IPO Porto (CES IPO 80/2014).

EBV detection
-------------

The presence of EBV infection was investigated in all patients using histological sections (3 µm slides) obtained from formalin-fixed paraffin-embedded (FFPE) tissue blocks. EBV was identified using the *in situ* hybridization (ISH) for the detection of EBV-encoded small RNAs (EBERs) in FFPE tissue samples. The ISH was performed using Epstein-Barr virus Probe/Antibody ISH Kit (Leica, Newcastle upon Tyne, United Kingdom) in association with Ultra Vision Large Volume Detection System Anti-Polyvalent, HRP (THERMO SCIENTIFIC, Fremont, United States) according to the manufacturer\'s instructions. Detection of hybrids is achieved by enzymatic reaction using the *ImmPACT^TM^ DAB* Peroxidase Substrate (VECTOR, Burlingame, CA, United States).

Only gastric tumours with presence of EBV infection in neoplastic cells were considered EBVaGC. For quality control, all EBV-positive cases and 10% of EBV-negative cases were retested and the results were 100% concordant. FFPE samples from a known EBV-positive post-transplant lymphoproliferative disorder (PTLD) tissue were used as positive controls and a sense probe for EBERs were used as the negative controls.

EBV latent proteins analysis
----------------------------

The presence of latent membrane protein 1 (LMP1) and latent membrane protein 2A (LMP2A) were evaluated with specific monoclonal antibodies in EBERs-positive gastric tissues using immunohistochemistry (IHC) (Table [1](#T1){ref-type="table"}). IHC was performed using the UltraVision Large Volume Detection System Anti-Polyvalent, HRP kit (THERMO SCIENTIFIC, Fremont, United States) and the signal was detected using the *ImmPACT^TM^ DAB* Peroxidase Substrate (VECTOR, Burlingame, CA, United States). All procedures were realized according to the manufacturer\'s instructions. PTLD samples with known positivity for LMP1 and LMP2A were used as positive controls. Gastric tumours were considered positive if 10% or more of the neoplastic cells were stained.

###### 

Antibodies used in immunohistochemistry

  **Protein**   **Primary Antibody**                                        **Dilution**   **Incubation**   **Retrieval method**                                          **Expression in gastric cells**
  ------------- ----------------------------------------------------------- -------------- ---------------- ------------------------------------------------------------- ---------------------------------
  LMP1          NCL-EBV-CS1-4, Leica, Newcastle upon Tyne, United Kingdom   1:100          3h, RT           15 min, microwave in *Vector*^®^ Antigen Unmasking Solution   Cytoplasm
  LMP2A         15F9, THERMO SCIENTIFIC, Fremont, United States             1:250          On, 4°C          Cytoplasm and membrane                                        

LMP1: Latent membrane protein 1; LMP2A: Latent membrane protein 2A; RT: Room temperature; On: Overnight.

Statistical analysis
--------------------

Statistical analysis was performed using the computer software IBM SPSS statistics for Macintosh, version 20.0 (IBM Corp, Armonk, NY, United States). *χ*^2^ or Fisher Exact-test was used to compare categorical variables, with a significance level of 5%. Overall survival was defined as the time between the date of surgery to the date of last follow-up (censored) or the date of patient death (event). Cases lost to follow-up and those ending in death from any cause other than gastric cancer were regarded as censored data during the analysis of survival rates. The differences in survival times between subgroups were calculated using the log-rank test and the Kaplan-Meier method was used to calculate survival probabilities.

RESULTS
=======

Characterization of the study population
----------------------------------------

The clinicopathological characteristics of all patients are described in (Table [2](#T2){ref-type="table"}). A total of 179 patients (108 males and 71 females) with mean age of 64 ± 12 were included in this study; the majority were submitted to gastrectomy (*n* = 177), wherein 100 were total resections and 77 partial resections, and the remaining 2 patients were submitted to esophagogastrectomy. Regarding the tumour localisation in stomach: 26 (14.5%) were found in the upper third (cardia or fundus); 46 (25.7%) in the middle region (body); and 107 (59.8%) in lower third (antrum or pylorus).

###### 

Patients characteristics and distribution of Epstein-Barr virus in gastric cancer patients *n* (%)

  **Characteristics**                     **All cases (*n* = 179)**   **EBV status**   ***P* value**   
  --------------------------------------- --------------------------- ---------------- --------------- ---------
  Gender, *n* = 179                                                                                    
  Male                                    108 (60.3)                  96 (88.9)        12 (11.1)       0.104
  Female                                  71 (51.5)                   68 (95.8)        3 (4.2)         
  Age, *n* = 179 (64.38 ± 12 yr of age)                                                                
  \< 65 yr of age                         90 (50.3)                   84 (93.3)        6 (6,7)         0.433
  ≥ 65 yr of age                          89 (49.7)                   80 (89.9)        9 (10.1)        
  Surgical procedure type, *n* = 179                                                                   
  Total gastrectomy                       100 (55.9)                  89 (89.0)        11 (11.0)       0.351
  Partial gastrectomy                     77 (43.0)                   73 (94.8)        4 (5.2)         
  Esophagogastrectomy                     2 (1.1)                     2 (100)          \-              
  Tumour localization, *n* = 179                                                                       0.087
  Upper third                             26 (14.5)                   22 (84.6)        4 (15.4)        
  Middle                                  46 (25.7)                   40 (87.0)        6 (13.0)        
  Lower third                             107 (59.8)                  102 (95.3)       5 (4.7)         
  Anatomical site, *n* = 179                                                                           
  Cardia                                  21 (11.7)                   19 (95.7)        2 (4.3)         0.041
  Fundus                                  5 (2.8)                     3 (60.0)         2 (40.0)        
  Body                                    46 (25.7)                   40 (87.0)        6 (13.0)        
  Pylorus                                 13 (7.3)                    12 (92.3)        1 (7.7)         
  Antrum                                  94 (52.5)                   90 (95.7)        4 (4.3)         
  Invasion pattern, *n* = 167                                                                          
  Infiltrative                            88 (52.7)                   83 (94.3)        5 (5.7)         0.237
  Expansive                               77 (46.1)                   67 (87.0)        10 (13.0)       
  Mixed                                   2 (1.1)                     2 (100)          \-              
  Differentiation, *n* = 167                                                                           
  Poor                                    91 (54.5)                   84 (92.3)        7 (7.7)         0.724
  Well+Moderate                           76 (45.5)                   69 (90.8)        7 (9.2)         
  Lymphovascular invasion, *n* = 179                                                                   
  Positive                                103 (57.5)                  94 (91.3)        9 (8.7)         0.841
  Negative                                76 (42.5)                   70 (92.1)        6 (7.9)         
  Histology WHO (2010), *n* = 179                                                                      
  Papillary adenocarcinoma                1 (0.6)                     1 (100)          \-              \<0.001
  Tubular adenocarcinoma                  92 (51.4)                   84 (91,3)        8 (8.7)         
  Mucinous adenocarcinoma                 5 (2.8)                     5 (100)          \-              
  Poorly cohesive carcinoma               51 (28.5)                   50 (98.0)        1 (2.0)         
  Mixed carcinoma                         25 (14.0)                   23 (92.0)        2 (8.0)         
  Medullary carcinoma                     3 (1.7)                     \-               3 (100)         
  Undifferentiated carcinoma              1 (0.6)                     1 (100)          \-              
  Adenosquamous carcinoma                 1 (0.6)                     \-               1 (100)         
  Primary tumour (T), *n* = 179                                                                        
  T1a                                     22 (12.3)                   22 (100)         \-              0.289
  T1b                                     18 (10.1)                   15 (83.3)        3 (16.7)        
  T2                                      25(14.0)                    24 (96.0)        1 (4.0)         
  T3                                      69 (38.5)                   60 (87.0)        9 (13.0         
  T4                                      7 (4.00)                    7 (100)          \-              
  T4a                                     37 (20.7)                   35 (94.6)        2 (5.4)         
  T4b                                     1 (0.56)                    1 (100)          \-              
  Regional lymph nodes (N), *n* = 179                                                                  
  N0                                      73 (40.8)                   67 (91.8)        6 (8.2)         0.024
  N1                                      23 (12.9)                   21 (91.3)        2 (8.7)         
  N2                                      31 (17.3)                   24 (77.4)        7 (22.6)        
  N3                                      8 (4.5)                     8 (100)          \-              
  N3a                                     23 (12.8)                   23 (100)         \-              
  N3b                                     21 (11.7)                   21 (100)         \-              
  Distant metastasis (M), *n* = 179                                                                    0.18
  M0                                      148 (82.7)                  133 (89.9)       15 (10.1)       
  M1                                      12 (6.70)                   12 (100)         \-              
  Mx                                      19 (10.6)                   19 (100)         \-              

*P* \< 0.05 were considered statistical significant. EBV: Epstein-Barr virus; WHO: World Health Organization.

Tumours were classified according to WHO (2010) classification system and the most common histological type was tubular adenocarcinoma (*n* = 92, 51.4%) followed by poorly cohesive carcinoma (*n* = 51, 28.5%), mixed carcinoma (*n* = 25, 14%) and less frequent were mucinous adenocarcinoma (*n* = 5, 2.8%), papillary adenocarcinomas (*n* = 1, 0.6%), undifferentiated carcinoma (*n* = 1, 0.6%), adenosquamous carcinoma (*n* = 1, 0.6%) and medullary carcinomas with lymphoid stroma (*n* = 3, 1.7%) (Table [2](#T2){ref-type="table"}). The correlation of histological type with anatomic localisation (data not shown), revealed that tubular type can be found in any stomach region, being more frequent in the lower third (56.5%) followed by upper and middle regions with 20.8% and 20.7%, respectively; poorly cohesive carcinomas were also more frequently located in the lower third (84.3%) and only 11.8% and 3.9% were in the middle and upper third, respectively; mixed adenocarcinomas were also more prevalent in lower third of the stomach with 72% of cases located in this region, with 16% in the middle and 12% in the upper region; and medullary carcinomas showed a similar distribution throughout the stomach with a percentage of 33.3% in all regions.

Regarding the characteristics of tumours, the most frequent invasion pattern was infiltrative (52.7% *vs* 46.1% expansive); the majority were poorly differentiated (54.5% *vs* 45.5% well or moderate differentiated); and lymphovascular invasion was extremely frequent (57.5% *vs* 42.5%) (Table [2](#T2){ref-type="table"}). The tumour staging revealed that the majority of cases (63.8%) were at Stage III and IV and in only 6.7% of all cases presented distant metastasis.

Regarding survival analysis, the median overall survival was of 45 mo (mean 36 ± 20.5; range 1-63). Furthermore, we observed that lymph node metastasis (N), lymphovascular and perineural permeation and infiltrative tumours had a significantly reduced median overall survival (*P \<* 0.001) (Figure [2A](#F2){ref-type="fig"}-D).

![Kaplan-Meier survival curves for overall survival. Comparison of overall survival in gastric cancer patients considering: A: Regional lymph node metastasis; B: Lymphovascular permeation; C: Perineural permeation; and D: Invasive pattern.](WJG-23-7292-g002){#F2}

Characterization of EBVaGC
--------------------------

In our series, out of the 179 patients with GC, fifteen patients (8.4%) were positive for EBV - (Table [2](#T2){ref-type="table"}). All EBV positive cases showed EBER positivity staining in \> 90 of tumour cells while it was not observed in normal mucosa with or without atrophic gastric, intestinal metaplasia or in stromal cells (endothelial cells and fibroblasts) (Figure [1](#F1){ref-type="fig"}). In addition, one case showed EBER positivity only in the lymphocytic infiltration but not in tumour cells and therefore it was classified as EBV-negative GC.

![Representative images of EBER-ISH positive results in different histological types of gastric cancer and their respective HE staining. A: Adenocarcinoma tubular; B: Adenocarcinoma tubular; C: Adenocarcinoma Mixed; D: Adenosquamous Carcinoma; E: Medullary caricnoma. HE: Hematoxylin and eosin stain; EBERs: EBV-encoded small RNAs. Figure [1](#F1){ref-type="fig"} Representative images of EBER-ISH positive results in different histological types of gastric cancer and their respective HE staining. A: Adenocarcinoma tubular; B: Adenocarcinoma tubular; C: Adenocarcinoma Mixed; D: Adenosquamous Carcinoma; E: Medullary caricnoma. HE: Hematoxylin and eosin stain; EBERs: EBV-encoded small RNAs.](WJG-23-7292-g001){#F1}

Despite no statistical differences, it was observed that EBVaGC is more frequent in males (11.1% *vs* 4.1% in females) and among patients with more than 65 years old (10.1% *vs* 6.7% in younger patients) (Table [2](#T2){ref-type="table"}). EBVaGC were not equally distributed among the stomach localisation (*P* = 0.087), being more often found in upper third and middle of the stomach than in the lower third; and regarding the anatomical site, it was more frequent (*P* = 0.041) in the body and fundus regions (40.0% and 13.0%, respectively) (Table [2](#T2){ref-type="table"}).

Results have revealed statistical significant differences (*P* \< 0.001) when comparing the distribution of EBV among different histological types according to WHO classification: EBV was detected in 8.7% (8/92) of tubular adenocarcinomas, 8.0% (2/25) of mixed carcinomas and only 2.0% (1/51) of poorly cohesive carcinomas. The results have also shown that all medullary (*n* = 3) and adenosquamous carcinomas (*n* = 1) were EBVaGC, while no EBV-positive case was identified in papillary adenocarcinomas and undifferentiated carcinomas (Table [2](#T2){ref-type="table"}). The analysis of the invasion pattern of the GC, revealed that tumours with expansive patterns have a higher prevalence of EBV when compared with infiltrative patterns (13.0% *vs* 5.7%, respectively), despite not statistically significant (*P* = 0.237) (Table [2](#T2){ref-type="table"}). No significant differences were also observed regarding the tumour differentiation and lymphovascular invasion (*P* \> 0.050).

The results show that EBVaGCs were associated with a low number of regional lymph nodes invasion (*P* = 0.024) and that all cases had no evidence of distant metastasis, nevertheless there was no evidence of association with tumour stage (*P* = 0.289). Additionally, comparing the number of lymph nodes with metastasis between EBVaGCs and EBV negative cases, it was observed that EBVaGC cases have a significant lower number (mean difference of 3.7; 95%CI: 1.8-1.5; *P* \< 0.001).

Table [3](#T3){ref-type="table"} resumes the individual characteristics of EBVaGC cases. Briefly, of the 15 EBVaGC cases 12 were males and 3 females with a mean age of 66 years old (range 44-82). Anatomically EBVaGCs were found in the body (*n* = 6), antrum (*n* = 4), fundus (*n* = 2), cardia (*n* = 2) and pylorus (*n* = 1). Regarding the histological subtypes, 8 were tubular adenocarcinoma, 3 were medullary carcinoma, 2 mixed carcinoma, 1 poorly cohesive carcinoma and 1 adenosquamous carcinoma. The invasion pattern showed that the majority of cases were expansive (*n* = 10/15) and regarding the differentiation, cases were equally distributed as poorly and moderately differentiated (*n* = 7 each). Moreover, there was no EBVaGC with distant metastasis.

###### 

Clinicopathological characteristics of Epstein-Barr virus-associated gastric cancers

  **ID**   **Gender**   **Age**   **Anatomic Site**   **WHO Classification**      **Invasion pattern**   **Differentiation**         ***n***   **TNM Classification**   **LMP-1**   **LMP-2A**
  -------- ------------ --------- ------------------- --------------------------- ---------------------- --------------------------- --------- ------------------------ ----------- ------------
  1        M            75        Body                Tubular Adenocarcinoma      Expansive              Poorly differentiated       6         T4aN2M0                  \-          \-
  2        M            80        Antrum              Tubular Adenocarcinoma      Expansive              Moderately differentiated   0         T3N0M0                   \-          \-
  3        M            56        Fundus              Tubular Adenocarcinoma      Expansive              Moderately differentiated   2         T2N1M0                   \-          \-
  4        M            80        Antrum              Tubular Adenocarcinoma      Expansive              Moderately differentiated   2         T3N0M0                   \-          \-
  5        M            64        Body                Tubular Adenocarcinoma      Expansive              Moderately differentiated   0         T3N2M0                   \-          (+)
  6        M            56        Fundus              Tubular Adenocarcinoma      Expansive              Moderately differentiated   0         T3N0M0                   \-          \-
  7        M            69        Body                Tubular Adenocarcinoma      Expansive              Moderately differentiated   3         T3N2M0                   \-          Inc.
  8        M            82        Cardia              Tubular Adenocarcinoma      Infiltrative           Moderately differentiated   4         T3N2M0                   \-          (+)
  9        M            55        Body                Mixed Carcinoma             Infiltrative           Poorly differentiated       3         T3N2M0                   \-          (+)
  10       F            66        Antrum              Mixed Carcinoma             NA                     Poorly differentiated       6         T1bN2M0                  \-          (+)
  11       F            68        Body                Medullary Carcinoma         Expansive              Poorly differentiated       1         T1bN1M0                  \-          \-
  12       M            52        Cardia              Medullary Carcinoma         Expansive              Poorly differentiated       0         T1bN0M0                  \-          \-
  13       M            44        Antrum              Medullary Carcinoma         Infiltrative           Poorly differentiated       0         T3N0M0                   \-          (+)
  14       F            65        Pylorus             Poorly cohesive carcinoma   Infiltrative           Poorly differentiated       0         T4aN0M0                  \-          \-
  15       M            76        Body                Adenosquamous carcinoma     Expansive              NA                          6         T3N2M0                   \-          (+)

N: Number of regional lymph nodes with metastasis; NA: Not available; (-): Negative result; (+): Positive result; Inc.: Inconclusive result; LMP1: Latent Membrane Protein 1; Latent Membrane Protein.

The survival analysis revealed that despite not statistically significant, EBVaGC patients have a higher overall survival (41 ± 1.8 mo *vs* 46 ± 5.9 mo, *P* = 0.222) (Figure [3](#F3){ref-type="fig"}).

![Comparison of overall survival in patients with Epstein-Barr virus-associated gastric carcinomas and Epstein-Barr virus-non associated gastric cancer. Kaplan-Meier curves with log-rank test estimate the overall survival of gastric cancer patients with and without Epstein-Barr virus (EBV)-associated gastric cancer.](WJG-23-7292-g003){#F3}

EBV latent proteins expression
------------------------------

Immunohistochemistry results revealed that all of EBVaGC cases were negative for LMP1 while 6 cases (40%) were positive for LMP2A and one case was inconclusive (Table [3](#T3){ref-type="table"}). The positive cases for LPM2A expression were randomly distributed among histological subtypes: tubular adenocarcinomas (*n* = 2), mixed carcinomas (*n* = 2), medullary carcinomas (*n* = 1) and adenosquamous carcinoma (*n* = 1) (Table [3](#T3){ref-type="table"}).

DISCUSSION
==========

Gastric carcinoma is a serious public health problem worldwide with high rates of mortality and Portugal has the highest gastric cancer mortality rates in Western European countries\[[@B2],[@B15]\]. The impact of classification systems in GC clinical decisions has been reduced and more recently two studies suggested a new classification based on molecular features of gastric tumours\[[@B11],[@B12]\]. In this new classification arises four new subtypes of gastric cancer: Epstein-Barr Virus positive tumours (EBVaGC); microsatellite unstable tumours; genomically stable tumours; and tumours with chromosomal instability (CIN) \[[@B11],[@B12]\].

Over the past 30 years, EBV infection has been reported in gastric cancer tumours\[[@B16]\]. Currently, it is accepted that about 10% of all GC represents a specific subset of gastric carcinomas that are associated with EBV carcinogenesis\[[@B17]\]. The gold-standard method for the detection of EBV in tissues is EBER-ISH and the decision to accept one case as EBV-associated should be taken considering the presence of EBERs expression in tumour cells and its absence in the normal surrounding tissue. In our study we found that 8.4% of GC in our population are EBV-associated, based on the EBERs expression in \> 90 of tumour cells and its absence in non-malignant or stromal cells. To the best of our knowledge, this is the first study reporting the prevalence of EBVaGC in the North Region of Portugal. The prevalence found in our population is in line with those reported in other studies, which have reported a prevalence ranging 2%-20%\[[@B5],[@B8],[@B18]\]. Similar data was found in other countries from Europe, including Netherlands (7.8%)\[[@B18]\], and Denmark (7.6%)\[[@B19]\] and also from Asiatic countries, such as South Korea (7.8%)\[[@B20]\] and Japan (8%)\[[@B21]\]. Geographic differences have been discussed as a possible reason for the variation of EBVaGC prevalence\[[@B8],[@B22]\] and some studies suggest that EBVaGC prevalence might be inversely correlated with the background incidence of GC\[[@B4]\]. The fact that Portugal has a higher incidence of GC when compared to other European countries seems to indicate that other factors apart from geography may be influencing the distribution of EBVaGC. Indeed, data from different meta-analyses have failed to show this association\[[@B8],[@B22]\].

We found that EBVaGC was more frequent in males than in females, which is in line with several studies and suggests an association with others factors, such as life style or hormonal risks\[[@B23]-[@B25]\]. In contrast with other reports, we have found no association between EBV status and patients' age\[[@B8],[@B26]\]. Regarding the tumour location, our study revealed a higher predominance of EBVaGC in upper third and middle of stomach and considering that *H. pylori* preferentially colonises the antral region, these results suggest a possible antagonism of EBV and *H. pylori* in gastric mucosa\[[@B27]-[@B29]\]. In fact, Minoura-Etoh et al\[[@B30]\] described in an *in vitro* study that reactive products from *H. pylori* seem to induce EBV reactivation from latently in infected gastric epithelial cells, which would avoid EBV transformation of gastric cells in the same areas of *H. pylori* colonization. Despite this association remains unclear, two recent studies have suggested that *H. pylori* may contribute for EBV-associated gastric carcinogenesis by recruiting to gastric tissue the inflammatory cells that are already infected by EBV in the majority of adults\[[@B7],[@B31]\]. This mechanism is not well understood and further studies should be made to establish if the recruitment of EBV-infected lymphoid cells might be the explanation for the infection and subsequent transformation of gastric epithelium. In our series, all EBVaGC cases had EBV only in tumour cells and not in normal tissues, nevertheless, we have found one case with EBV only in the lymphocytic infiltration, which we considered negative for EBV, and therefore more studies are required to understand if in such cases tumour cells will be later infected by EBV.

The association between EBV and gastric histological types remains controversial, indeed while one meta-analysis regarding EBV in gastric carcinoma has shown that EBVaGC was associated with diffuse histological type according to Lauren classification\[[@B5],[@B8]\], two other meta-analyses did not find any association between EBV and histology subtypes\[[@B22],[@B32]\]. Several studies demonstrated a strong EBV association with diffuse type while others have reported a similar prevalence between intestinal and diffuse types (classified in our study as poorly cohesive according to the WHO)\[[@B9],[@B18],[@B33],[@B34]\]. Our study revealed that EBVaGC are more frequently associated with specific histologic subtypes. EBVaGC represent about 8% of tubular (intestinal type in the Lauren classification system) and mixed types while it was only found in 2% (*n* = 1/51) of poorly cohesive carcinomas (diffuse type in the Lauren classification system). These distinct features show that the differences in the GC histological distribution among different populations may impact on the prevalence of EBVaGC subtype, which should gather importance on the detection of EBV in GC. As expected, all medullary carcinomas, also known as gastric carcinoma with lymphoid stroma or lymphoepithelioma-like gastric carcinoma, were EBV positive\[[@B35]\]. In fact, EBV association with gastric cancer was first described in lymphoepithelioma-like gastric subtype and the literature shows that more than 80% of these cases are EBV-positive\[[@B5],[@B22],[@B36]\].

Some studies have revealed that EBVaGC is associated with poor or moderate differentiation of gastric cancer tissues\[[@B9],[@B24]\]. In accordance with these reports, our study showed that 100% of cases were poorly or moderately differentiated and that these differentiation patterns seem to be associated with the histological types. This evidence may be a significant mark of EBVaGC tumours and may provide important information regarding the clinical approach to these tumours.

All these data support the evidence that recent studies have shown by considering EBVaGC as a distinct clinicopathological entity due to its individual features\[[@B11],[@B12],[@B18],[@B37]\]. Interestingly, we found that EBVaGC had a significantly lower number of regional lymph nodes with metastasis and that none have a distant metastasis. Additionally, when analysing the overall survival of EBVaGC compared to all other cases it was observed that EBVaGC seems to have an improved survival, that despite not statistically significant may be explained by the low number of cases in our population. Several studies have reported a better overall survival of EBVaGC, especially in Asiatic populations suggesting that the explanation for this better overall survival could be due to the low frequency of lymph node involvement and distant metastasis\[[@B18],[@B23],[@B24],[@B38]\]. In Portugal, GC remains at high mortality rates due to the late diagnosis of this disease and these patients are frequently only treated with chemo/radiotherapy. In our study we have included only patients with available tissue sample from surgical procedures and therefore we had not included patients that had received only chemo/radiotherapy, therefore our findings should be applied in patients with recommendation for total or partial gastrectomy as according to the ESMO Clinical Practice Guidelines for Diagnosis, Follow-up\[[@B39]\]. Moreover, others factors may be influencing patients survival and this question should be explored with further large-scale studies.

To elucidate the role of EBV in the pathogenesis of gastric carcinoma several studies have focused on the study of EBV latent proteins expression in gastric tumour cells\[[@B40]-[@B42]\]. As expect, in our study LMP1 was not found in any of EBVaGC cases and, in fact, literature also shows that LMP1 is generally absent in EBVaGC except for the data reported in a few studies, which have detected low *albeit* detectable levels of LMP1 mRNA\[[@B41]-[@B43]\]. The absence of LMP1 expression in EBV positive cases suggests that LMP1 may not be needed for gastric carcinogenesis or at least not for sustaining the already established malignant tumours. Regarding LMP2A, our results demonstrated that EBV LMP2A is expressed in 40% of EBVaGC cases that is in line with previous studies\[[@B41],[@B44]\]. Recent studies have pointed that LMP2A seems to have an important role contributing to malignant state in epithelial cells by inducing the genome hypermethylation through up-regulation of DNMT1 and phosphorylation of STAT3 and thus contributing for the carcinogenic potential of the cells\[[@B45]\]. A systematic review performed by our group has shown that EBVaGC are usually associated with a distinct latency pattern, characterized by the expression of EBERs, EBNA1, LMP2A and EBV microRNAs. Furthermore, literature also shows that EBV latency I pattern, which is characterized by the expression of EBERs, EBNA 1 and EBV microRNAs\[[@B46]\], has been also frequently found among EBVaGC tumours\[[@B47],[@B48]\]. In line with this, our study demonstrates that the majority of our cases express EBERs with absence of LMP1 and LMP2A, however, 40% of our cases also expressed LMP2A, which does not fit into the standard EBV latency patterns. In fact, literature has described this distinct pattern as latency II-like and has also reported that lytic transcripts such as BARF0 and BARF1 can also be found within EBV-associated gastric neoplasias\[[@B44],[@B49]\]. Our data reinforces that the clarification of which EBV transcripts (including lytic transcripts and EBV microRNAs) are expressed in gastric tumours assumes a great importance to understand the viral carcinogenesis in gastric cancer and may contribute for the identification of new molecular targets for treatment.

In our study, EBVaGC represents 8.4% of our population with gastric cancer and it is more frequent among tubular adenocarcinomas and medullary carcinomas rather than poorly cohesive carcinomas. EBVaGCs were more common in upper and middle regions of the stomach; were correlated with a lower number of regional lymph nodes with metastasis and with no distant metastasis. The results also revealed that EBVaGC patients seem to have an improved survival and better prognosis. These features suggest that EBVaGC is a distinct subtype of gastric cancer and that the mechanisms of carcinogenesis should be further investigated for particular therapeutic targets

COMMENTS
========

Background
----------
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